Peptide News Digest

Novo Q1 Wegovy Pill $354M (~2× Consensus), Guidance Tightened, Wegovy HD STEP UP Detail, Barclays LLY $1,400, BMC DualPep-ALO Hair Peptide, ITM-11 Aug PDUFA

Novo Q1 prints Wegovy pill at $354M (2× consensus), tightens guidance; Barclays + Cantor + BofA hike LLY targets; BMC DualPep-ALO hair peptide; ITM-11 PDUFA August 28.

10 stories · Covering industry, clinical-trials, research, regulatory

Editor's Note

Novo Nordisk's Q1 2026 print on May 6 lifted the entire GLP-1 narrative. Wegovy pill posted DKK 2.26 billion (~$354M) in Q1 sales — almost twice the 1.16-billion-kroner analyst consensus — on roughly 1.3 million Q1 prescriptions and 2 million-plus cumulative scripts since the January 5 launch. Total reported Q1 net sales hit DKK 96.82B (+24% YoY) and operating profit climbed 54% to DKK 59.62B; full-year guidance tightened from a 5–13% sales-and-operating-profit decline to a 4–12% decline. Wegovy HD 7.2 mg, approved in March and launched April 7, contributed to the premium tier with its STEP UP 21% mean weight loss. Lilly's stock had its own moment: Barclays raised its LLY price target to $1,400 May 5 on tirzepatide momentum, with Cantor Fitzgerald lifting to $1,230 and BofA to $1,294 in the same window — analyst consensus forecasts 24% 12-month upside. Behind the GLP-1 fight, BMC Biotechnology published a paper on DualPep-ALO, a novel synthetic cell-penetrating peptide that promotes hair growth through anti-inflammatory and pro-regenerative pathways in preclinical models. ITM's Lu-edotreotide-177 (ITM-11) sets up the next major non-GLP-1 peptide PDUFA on August 28, 2026, in gastroenteropancreatic neuroendocrine tumors. The ResearchAndMarkets PDC market report counts six peptide-drug conjugates in Phase 3 and ~96 in development, and CagriSema's higher-dose Phase 3 trial is now slated for H2 2026 after February's failure to match Zepbound.

Industry

Novo Nordisk Q1 2026 (May 6): Wegovy Pill Posts $354M Q1 Sales (~2× Consensus), 2M+ Prescriptions Since Launch; Operating Profit +54%, Guidance Tightened to -4 to -12%

Novo Nordisk reported Q1 2026 results May 6: net sales of DKK 96.82B (+24% YoY) and operating profit of DKK 59.62B (+54%). The Wegovy pill drove the print with DKK 2.26B (~$354M) in Q1 sales — almost double the DKK 1.16B analyst consensus — on roughly 1.3 million Q1 prescriptions and more than 2 million cumulative US prescriptions since the January 5 launch. Injectable Wegovy sales rose 12% YoY to DKK 18.2B. Ozempic sales fell 8% YoY but came in above expectations. The company tightened full-year guidance to a 4–12% sales-and-operating-profit decline at constant exchange rates, narrower than the prior 5–13% range. NVO US-listed shares rose roughly 6% on the print.

#novo-nordisk #q1-2026-earnings #wegovy-pill #ozempic #guidance-raise #iqvia
Clinical Trials

Wegovy HD 7.2 mg Q1 Contribution: STEP UP Trial 21% Mean Weight Loss at 72 Weeks Anchors Premium-Tier Adoption

Novo Nordisk's Q1 print clarified that Wegovy HD (semaglutide 7.2 mg injection) — approved by the FDA in March and launched in the US on April 7 — is contributing to the premium-tier injectable mix alongside the standard 2.4 mg dose. The STEP UP trial showed 21% mean weight loss at 72 weeks if all patients stayed on treatment (19% regardless), with 89% on 7.2 mg achieving ≥5% body-weight reduction versus 38% with placebo. The label requires four-plus weeks of tolerability on semaglutide 2.4 mg before stepping up. NovoCare prices the 7.2 mg dose at $399/month self-pay and as low as $25 for many commercially insured patients via the savings offer. Dysesthesia at 22% on 7.2 mg vs. 6% on 2.4 mg and 0.3% on placebo is the only meaningful safety signal beyond the broader GLP-1 class.

#wegovy-hd #novo-nordisk #step-up #semaglutide #high-dose #obesity
Industry

Barclays Hikes LLY Price Target to $1,400 on Tirzepatide Momentum, Reiterates Overweight Rating (May 5)

Barclays analyst Emily Field raised her price target on Eli Lilly to $1,400 from $1,350 May 5 and reiterated an Overweight rating, citing tirzepatide momentum continuing to outpace the GLP-1 class and easing concerns around the Foundayo launch trajectory. LLY stock had recovered roughly 11% off the May 4 Foundayo FAERS-driven dip to about $966 by mid-week. Barclays simultaneously trimmed its 2026 Foundayo revenue estimate to approximately $1B (vs. ~$1.4B consensus) on the early IQVIA gap to Wegovy pill, but the higher headline target reflects confidence that Mounjaro and Zepbound's volume growth more than absorbs Foundayo's slower start.

#barclays #eli-lilly #lly-stock #tirzepatide #price-target #analyst-upgrade
Industry

Cantor Fitzgerald Lifts LLY Price Target to $1,230 and BofA to $1,294 Following Q1 Beat and Foundayo FAERS Recovery

Multiple Wall Street firms raised LLY price targets in the May 5–6 window. Cantor Fitzgerald lifted its target to $1,230, BofA to $1,294, and the broader analyst consensus by 19 firms now sits at $1,228 (24.15% upside over 12 months) per the May 6 update, with a Buy consensus rating. The driver: tirzepatide's Q1 +125% global growth, the Mounjaro/Zepbound volume re-rating, the May 1 stock recovery from the Foundayo hepatic-failure FAERS report, and Lilly's response that no DILI signal exists across the 11,000-patient ACHIEVE+ATTAIN program. RBC Capital framed the FAERS event as 'baseline noise.'

#eli-lilly #lly-stock #cantor-fitzgerald #bofa #analyst-consensus #price-target
Research

BMC Biotechnology: DualPep-ALO Synthetic Cell-Penetrating Peptide Promotes Hair Growth via Anti-Inflammatory + Pro-Regenerative Pathways in Preclinical Models

A 2026 BMC Biotechnology paper introduces DualPep-ALO, a novel synthetic cell-penetrating peptide engineered to promote hair growth by restoring the follicular microenvironment and stimulating regenerative pathways. In preclinical models, DualPep-ALO showed potent antioxidant, anti-inflammatory, and pro-regenerative effects, restoring follicular vitality through multimodal biological pathways. The paper supports the peptide's potential as a topical CPP-based agent for hair loss, warranting further clinical investigation. The work joins a 2026 wave of peptide-led hair-growth research alongside copper-peptide GHK-Cu's surge in the cosmetic and longevity-clinic space and the broader 'peptide therapy' search trend that Drexel's May 5 Q&A flagged as a 1,016% YoY rise for GHK-Cu specifically.

#dualpep-alo #cell-penetrating-peptide #hair-growth #bmc-biotechnology #topical #preclinical
Clinical Trials

Novo CagriSema Higher-Dose Phase 3 Trial Set for H2 2026 After February Failure to Match Zepbound; FDA Filing Already Submitted with Late-2026 Decision Window

Novo Nordisk confirmed in its Q1 2026 commentary that a higher-dose CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) Phase 3 trial will start in the second half of 2026, in response to the February 23 readout where the lower-dose 2.4/2.4 mg arm achieved 23% mean weight loss vs. 25.5% on tirzepatide 15 mg over 84 weeks — failing the non-inferiority primary endpoint. The original CagriSema FDA filing is already submitted with a decision expected in late 2026; the higher-dose program is meant to position Novo for a more competitive head-to-head against tirzepatide before the retatrutide TRIUMPH readouts arrive. ECO 2026 in Istanbul (May 12–15) will deliver additional CagriSema data alongside Wegovy 7.2 mg.

#cagrisema #novo-nordisk #phase-3 #cagrilintide #semaglutide #redefine
Industry

Peptide-Drug Conjugate Market Report (April 21, 2026): 6 PDCs in Phase III, ~96 in Development, Clinical Trial Registrations Up 34% YoY

ResearchAndMarkets published an April 21 PDC market landscape report counting six peptide-drug conjugates currently in Phase III trials and approximately 96 in development across the global pipeline. Lutathera remains the only FDA-approved PDC after Pepaxto's withdrawal, though Pepaxto retains EMA and MHRA approval. The report flags 34% year-over-year growth in clinical-trial registrations for peptide-based oncology compounds, with the majority targeting solid tumors previously considered peptide-resistant. Phase 2 ADC peptide-linker data released in early 2026 shows tumor-specific payload delivery rates above 85% — nearly double the 2023 benchmark — driven by the proteolytic-stability work that lets linker peptides survive serum peptidase degradation long enough to reach solid tumors.

#peptide-drug-conjugate #pdc-market #phase-3 #lutathera #oncology #linker-chemistry
Regulatory

ITM Lu-edotreotide-177 (ITM-11) FDA PDUFA Set for August 28, 2026 — Next Major Peptide Radioligand Decision in Gastroenteropancreatic Neuroendocrine Tumors

ITM Isotope Technologies Munich's Lu-edotreotide-177 (branded ITM-11), a peptide radioligand therapy targeting somatostatin receptor 2 (SSTR2) in gastroenteropancreatic neuroendocrine tumors, has an FDA decision goal of August 28, 2026. If approved, ITM-11 would expand US PRRT options beyond Novartis's Lutathera, which has held the SSTR2 PRRT category since 2018. Companion radiopharmaceutical kit Ga 68 edotreotide (LNTH-2501) supports PET imaging for SSTR-positive NETs. The August PDUFA sits alongside the July 23–24 PCAC meeting on seven 503A peptides and Roche's mid-2026 enicepatide+petrelintide combination Phase 2 start as the next-quarter peptide regulatory inflection points.

#itm-11 #lu-edotreotide #prrt #neuroendocrine-tumors #sstr2 #fda #pdufa
Research

Asia-Pacific Journal of Clinical Oncology 2026: Personalized Cancer Vaccine Pipeline Hits 31 Peptide-Vaccine Trials, 15 Dendritic Cell, 13 RNA — Most Targeting Solid Tumors

A 2026 Asia-Pacific Journal of Clinical Oncology review of the personalized cancer vaccine pipeline counts 31 active peptide-vaccine trials — the most-used personalized vaccine platform — followed by dendritic-cell vaccines (15) and RNA vaccines (13). Phase 1 trials dominate the landscape (over 90% of studies), with US (44%) and China (24%) leading by registration count. Solid tumors (brain, pancreatic, breast) are the primary targets. Lead programs covered on this site that fit the framework: ELI-002 KRAS amphiphile vaccine (AMPLIFY-201), autogene cevumeran (BioNTech/Genentech) in pancreatic cancer, EVX-01 (Evaxion) in melanoma, GP2/GLSI-100 (Greenwich) in HER2 breast cancer, ENA101 (Enara), MVP-S (BioVaxys) in ovarian, and the multipeptide melanoma vaccination 20-year survival data.

#peptide-vaccine #personalized-cancer-vaccine #neoantigen #asia-pacific-journal #pipeline #solid-tumors
Industry

Eli Lilly Stock +11% Past Week After Q1 Beat + Foundayo FAERS Recovery; Analyst Consensus Forecasts 24% 12-Month Upside

Eli Lilly stock has gained roughly 11% over the past week, recovering from the May 4 Foundayo hepatic-failure FAERS report-driven 3% premarket dip and consolidating gains from the April 30 Q1 beat. Per the May 6 analyst consensus across 19 covering firms, LLY now carries an average 12-month price target of $1,228 — implying 24.15% upside from current $966 — with a Buy consensus rating. The recovery framework: tirzepatide volume (+125% global Q1 growth) anchors the floor, retatrutide TRIUMPH program (seven Phase 3 readouts due in 2026) anchors the upside, the small-molecule manufacturing economics of Foundayo offset peptide CDMO bottlenecks, and Pfizer's MariTide/MET-097i and Novo's CagriSema higher-dose program don't read out until 2027.

#eli-lilly #lly-stock #analyst-consensus #foundayo-recovery #tirzepatide #retatrutide